Business
business

Thirsty: Weed company CEO really wants to get bought by beer company

Sometimes when you’re looking for a partner, you’ve just gotta shoot your shot. 

Ben Kovler, the CEO of cannabis company Green Thumb, did just that, The Wall Street Journal is reporting. On Sunday, Kovler wrote the chairman of Boston Beer, the maker of Sam Adams, pitching a potential merger that would allow this new combined company to spark new ideas in pre-rolled joints, edibles, drinks. 

The likelihood of a deal doesn’t seem very high given weed is still illegal at the federal level, though it has been gaining ground in states across the country. It wouldn’t be a cheap buy, either: Canada-based Green Thumb trades over-the-counter with a market cap around $2.5 billion, while Boston Beer sits at roughly $3.6 billion, with a couple hundred million in cash on its balance sheet. And the “please buy me” cold call doesn’t work too often in the land of deals.

Meanwhile, Boston Beer has been dealing with its own potential suitor – WSJ reported last week that Japanese whisky producer Suntory was in early talks to potentially acquire the beer maker. Interestingly, sometimes swallowing up a smaller company to make yourself a more expensive merger target can work to dampen the interest of an unwelcome suitor.

The likelihood of a deal doesn’t seem very high given weed is still illegal at the federal level, though it has been gaining ground in states across the country. It wouldn’t be a cheap buy, either: Canada-based Green Thumb trades over-the-counter with a market cap around $2.5 billion, while Boston Beer sits at roughly $3.6 billion, with a couple hundred million in cash on its balance sheet. And the “please buy me” cold call doesn’t work too often in the land of deals.

Meanwhile, Boston Beer has been dealing with its own potential suitor – WSJ reported last week that Japanese whisky producer Suntory was in early talks to potentially acquire the beer maker. Interestingly, sometimes swallowing up a smaller company to make yourself a more expensive merger target can work to dampen the interest of an unwelcome suitor.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.